Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.76 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239364 | 0.90 | DGAT2 (0.62) | DGAT2JAK2 | |
| SCHEMBL20252421 | 0.89 | DGAT2 (0.86) | DGAT2HRH4 | |
| SCHEMBL20239199 | 0.86 | DGAT2 (1.00) | DGAT2HRH4 | |
| SCHEMBL20239208 | 0.82 | DGAT2 (0.53) | DGAT2LTA4HKCNH2GRIN1GRIN2B | |
| SCHEMBL20239246 | 0.81 | DGAT2 (0.50) | DGAT2LTA4HKCNH2GRIN1GRIN2B | |
| SCHEMBL20239259 | 0.80 | DGAT2 (0.49) | DGAT2LTA4HKCNH2GRIN1GRIN2B | |
| SCHEMBL20239298 | 0.76 | DGAT2 (0.81) | DGAT2EGFR | |
| SCHEMBL20239363 | 0.76 | DGAT2 (0.81) | DGAT2 | |
| SCHEMBL20239256 | 0.76 | DGAT2 (0.81) | DGAT2HRH4MCHR1 | |
| SCHEMBL20239147 | 0.74 | DGAT2 (0.76) | DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | DGAT2 1/4885HRH4 2044/4885LTA4H 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.